Adaptimmune has an extensive portfolio of intellectual property covering its technology platform and T-cell therapies. Our patent portfolio covers a number of platform technology patents for the engineering and safety testing of T-cell receptors and T-cell therapies. We also have composition of matter patents and patent applications covering our T-cell therapies, including our lead NY-ESO and MAGE-A10 T-cell therapies.